Gary Rosner

Research output

Research output per year 1984 1992 1994 1995 1996 1997 2004 2005 2007 2008 2009 2014 2015 2017 2018 2020 2021 2024

• 195 Article
• 8 Review article
• 6 Comment/debate
• 4 Letter
• 1 More
  • 1 Chapter

Research output per year

Research output per year

Search results

• 2024

  Bayesian and Frequentist Approaches to Rescuing Disrupted Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions

  Kunz, C. U., Tarima, S., Rosner, G. L., Emsley, R., Bauer, M., Jennison, C., Rosenberger, J. L., Stallard, N., Zohar, S. & Flournoy, N., 2024, (Accepted/In press) In: Statistics in Biopharmaceutical Research.

  Research output: Contribution to journal › Article › peer-review

  Open Access
• 2023

  A Bayesian model with application for adaptive platform trials having temporal changes

  Wang, C., Lin, M., Rosner, G. L. & Soon, G., Jun 2023, In: Biometrics. 79, 2, p. 1446-1458 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Viruses 76%
  • Bayesian Model 73%
  • clinical trials 69%
  • Hidden Markov models 65%
  • Product development 65%

• A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study

  Hahn, N. M., O'Donnell, M. A., Efstathiou, J. A., Zahurak, M., Rosner, G. L., Smith, J., Kates, M. R., Bivalacqua, T. J., Tran, P. T., Song, D. Y., Baras, A. S., Matoso, A., Choi, W., Smith, K. N., Pardoll, D. M., Marchionni, L., McGuire, B., Grace Phelan, M., Johnson, B. A., O'Neal, T., & 21 othersMcConkey, D. J., Rose, T. L., Bjurlin, M., Lim, E. A., Drake, C. G., McKiernan, J. M., Deutsch, I., Anderson, C. B., Lamm, D. L., Geynisman, D. M., Plimack, E. R., Hallman, M. A., Horwitz, E. M., Al-Saleem, E., Chen, D. Y. T., Greenberg, R. E., Kutikov, A., Guo, G., Masterson, T. A., Adra, N. & Kaimakliotis, H. Z., Jun 2023, In: European Urology. 83, 6, p. 486-494 9 p.

  Research output: Contribution to journal › Article › peer-review

  • durvalumab 100%
  • Mycobacterium bovis 62%
  • Urinary Bladder Neoplasms 55%
  • Radiotherapy 40%
  • Neoplasms 18%

• A study of using epigenetic modulators to enhance response to pembrolizumab (MK-3475) in microsatellite stable advanced colorectal cancer

  Baretti, M., Murphy, A. G., Zahurak, M., Gianino, N., Parkinson, R., Walker, R., Lopez-Vidal, T. Y., Zheng, L., Rosner, G., Ahuja, N., Kurt, S. & Azad, N. S., Dec 2023, In: Clinical Epigenetics. 15, 1, 74.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • pembrolizumab 100%
  • Microsatellite Repeats 74%
  • Epigenomics 62%
  • Colorectal Neoplasms 56%
  • Histone Deacetylases 27%

• Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response

  Lee, S. H. R., Yang, W., Gocho, Y., John, A., Rowland, L., Smart, B., Williams, H., Maxwell, D., Hunt, J., Yang, W., Crews, K. R., Roberts, K. G., Jeha, S., Cheng, C., Karol, S. E., Relling, M. V., Rosner, G. L., Inaba, H., Mullighan, C. G., Pui, C. H., & 2 othersEvans, W. E. & Yang, J. J., Jan 2023, In: Nature medicine. 29, 1, p. 170-179 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Glucocorticoid 100%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 76%
  • Heterogeneity 71%
  • Molecular Cluster 50%
  • Pediatrics 49%
• 2022

  A Bayesian Decision-Theoretic Design for Simultaneous Biomarker-Based Subgroup Selection and Efficacy Evaluation

  Wang, Z., Wang, F., Wang, C., Zhang, J., Wang, H., Shi, L., Tang, Z. & Rosner, G. L., 2022, In: Statistics in Biopharmaceutical Research. 14, 4, p. 568-579 12 p.

  Research output: Contribution to journal › Article › peer-review

  • Biomarkers 100%
  • Efficacy 82%
  • Biological Marker 70%
  • Evaluation 56%
  • Subgroup 51%
• 2021

  A batch-effect adjusted Simon's two-stage design for cancer vaccine clinical studies

  Wang, C., Wang, Z., Rosner, G. L., Huh, W. K., Roden, R. B. S. & Bae, S., Sep 2021, In: Biometrics. 77, 3, p. 1075-1088 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • cancer vaccines 100%
  • Vaccines 73%
  • Two-stage Design 73%
  • Vaccine 69%
  • Cancer Vaccines 65%

• A feasibility study of combined epigenetic and vaccine therapy in advanced colorectal cancer with pharmacodynamic endpoint

  Bever, K. M., Thomas, D. L., Zhang, J., Diaz Rivera, E. A., Rosner, G. L., Zhu, Q., Nauroth, J. M., Christmas, B., Thompson, E. D., Anders, R. A., Judkins, C., Liu, M., Jaffee, E. M., Ahuja, N., Zheng, L. & Azad, N. S., Dec 2021, In: Clinical Epigenetics. 13, 1, 25.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • guadecitabine 100%
  • Combined Vaccines 68%
  • Active Immunotherapy 65%
  • Feasibility Studies 52%
  • Epigenomics 43%

• Appropriate systemic therapy dosing for obese adult patients with cancer: ASCO Guideline update

  Griggs, J. J., Bohlke, K., Balaban, E. P., Dignam, J. J., Hall, E. T., Harvey, R. D., Hecht, D. P., Klute, K. A., Morrison, V. A., Pini, T. M., Rosner, G. L., Runowicz, C. D., Shayne, M., Sparreboom, A., Turner, S., Zarwan, C. & Lyman, G. H., Jun 20 2021, In: Journal of Clinical Oncology. 39, 18, p. 2037-2048 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Guidelines 100%
  • Antineoplastic Agents 89%
  • Immunotherapy 82%
  • Drug Therapy 54%
  • Neoplasms 50%

• Discovering interactions using covariate informed random partition models

  Page, G. L., Quintana, F. A. & Rosner, G. L., 2021, In: Annals of Applied Statistics. 15, 1, p. 1-21 21 p.

  Research output: Contribution to journal › Article › peer-review

  • Chemotherapy 100%
  • Pharmacokinetics 94%
  • Random Partitions 94%
  • Covariates 56%
  • Machine learning 48%
  1 Scopus citations

• Feature engineering and machine learning for causality assessment in pharmacovigilance: Lessons learned from application to the FDA Adverse Event Reporting System

  Kreimeyer, K., Dang, O., Spiker, J., Muñoz, M. A., Rosner, G., Ball, R. & Botsis, T., Aug 2021, In: Computers in Biology and Medicine. 135, 104517.

  Research output: Contribution to journal › Article › peer-review

  • Pharmacovigilance 100%
  • Machine Learning 86%
  • United States Food and Drug Administration 76%
  • Causality 71%
  • Datasets 60%

• Leveraging real-world evidence for determining performance goals for medical device studies

  Wang, C., Rosner, G. L., Bao, T., Lu, N., Chen, W. C., Li, H., Tiwari, R., Xu, Y. & Yue, L. Q., Dec 20 2021, In: Statistics in Medicine. 40, 29, p. 6577-6589 13 p.

  Research output: Contribution to journal › Article › peer-review

  • Evidence 100%
  • Equipment and Supplies 72%
  • Performance 71%
  • Clinical Studies 55%
  • Target 51%

• Meta-analysis of rare adverse events in randomized clinical trials: Bayesian and frequentist methods

  Hong, H., Wang, C. & Rosner, G. L., Feb 2021, In: Clinical Trials. 18, 1, p. 3-16 14 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Bayes Theorem 100%
  • Meta-Analysis 61%
  • Randomized Controlled Trials 55%
  • Rosiglitazone 29%
  • Device Approval 20%
  2 Scopus citations

• Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments

  Tannock, I. F., Ratain, M. J., Goldstein, D. A., Lichter, A. S., Rosner, G. L. & Saltz, L. B., Mar 20 2021, In: Journal of Clinical Oncology. 39, 9, p. 950-955 6 p.

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
• 2020

  A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation

  ETCTN-8922 study team, Feb 2020, In: Biology of Blood and Marrow Transplantation. 26, 2, p. 300-306 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Sorafenib 100%
  • Homologous Transplantation 91%
  • Acute Myeloid Leukemia 77%
  • Prospective Studies 51%
  • Transplants 30%
  13 Scopus citations

• Bayesian copy number detection and association in large-scale studies

  Cristiano, S., McKean, D., Carey, J., Bracci, P., Brennan, P., Chou, M., Du, M., Gallinger, S., Goggins, M. G., Hassan, M. M., Hung, R. J., Kurtz, R. C., Li, D., Lu, L., Neale, R., Olson, S., Petersen, G., Rabe, K. G., Fu, J., Risch, H., & 4 othersRosner, G. L., Ruczinski, I., Klein, A. P. & Scharpf, R. B., Sep 7 2020, In: BMC cancer. 20, 1, 856.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Genome-Wide Association Study 100%
  • Pancreatic Neoplasms 90%
  • Oncogenes 45%
  • Uncertainty 43%
  • Noise 43%

• BAYESIAN INFERENCE FOR LATENT CHAIN GRAPHS

  Lu, D., de Iorio, M., Jasra, A. & Rosner, G. L., Mar 2020, In: Foundations of Data Science. 2, 1, p. 35-54 20 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Feature Model 100%
  • Sequential Monte Carlo Methods 99%
  • Chain Graph 93%
  • Biological Networks 89%
  • Financial Time Series 89%

• Bayesian Methods in Regulatory Science

  Rosner, G. L., Apr 2 2020, In: Statistics in Biopharmaceutical Research. 12, 2, p. 130-136 7 p.

  Research output: Contribution to journal › Article › peer-review

  • Bayes Theorem 100%
  • Bayesian Methods 88%
  • Clinical Trials 77%
  • Safety 70%
  • Drug 43%

• Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015

  the Translational Breast Cancer Research Consortium (TBCRC), Jun 1 2020, In: Breast Cancer Research and Treatment. 181, 3, p. 623-633 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Hand-Foot Syndrome 100%
  • Capecitabine 87%
  • Single Nucleotide Polymorphism 58%
  • Breast Neoplasms 44%
  • Odds Ratio 29%
  2 Scopus citations

• Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period

  O’Sullivan, C. C., Irshad, S., Wang, Z., Tang, Z., Umbricht, C., Rosner, G. L., Christianson, M. S., Stearns, V. & Smith, K. L., Apr 1 2020, In: Breast Cancer Research and Treatment. 180, 3, p. 695-706 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Breast Neoplasms 100%
  • Pregnancy 94%
  • Drug Therapy 8%
  • Recurrence 7%
  • Control Groups 7%
  3 Scopus citations

• Discussion on “Predictively consistent prior effective sample sizes,” by Beat Neuenschwander, Sebastian Weber, Heinz Schmidli, and Anthony O'Hagan

  Rosner, G. L. & Müller, P., Jun 1 2020, In: Biometrics. 76, 2, p. 599-601 3 p.

  Research output: Contribution to journal › Article › peer-review

  • Effective Sample Size 100%
  • Beat 87%
  • Sample Size 59%
  • Bayesian Model 37%
  • Methodology 24%

• Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide

  DeZern, A. E., Zahurak, M. L., Symons, H. J., Cooke, K. R., Rosner, G. L., Gladstone, D. E., Huff, C. A., Swinnen, L. J., Imus, P., Borrello, I., Wagner-Johnston, N., Ambinder, R. F., Luznik, L., Bolaños-Meade, J., Fuchs, E. J., Jones, R. J. & Brodsky, R. A., Apr 28 2020, In: Blood Advances. 4, 8, p. 1770-1779 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haploidentical Transplantation 100%
  • Aplastic Anaemia 74%
  • Bone Marrow Transplantation 63%
  • Cyclophosphamide 57%
  • Transplants 17%
  18 Scopus citations

• Individualized treatment effects with censored data via fully nonparametric Bayesian accelerated failure time models

  Henderson, N. C., Louis, T. A., Rosner, G. L. & Varadhan, R., Jan 1 2020, In: Biostatistics. 21, 1, p. 50-68 19 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Heterogeneous Treatment Effects 100%
  • Censored Data 93%
  • Accelerated Failure Time Model 85%
  • Bayesian Model 71%
  • Treatment Effects 71%
  9 Scopus citations

• Information Visualization Platform for Postmarket Surveillance Decision Support

  Spiker, J., Kreimeyer, K., Dang, O., Boxwell, D., Chan, V., Cheng, C., Gish, P., Lardieri, A., Wu, E., De, S., Naidoo, J., Lehmann, H., Rosner, G. L., Ball, R. & Botsis, T., Sep 1 2020, In: Drug Safety. 43, 9, p. 905-915 11 p.

  Research output: Contribution to journal › Article › peer-review

  • Safety 100%
  • Natural Language Processing 19%
  • Boidae 18%
  • Informatics 16%
  • Automation 15%
  1 Scopus citations

• Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer

  Reuss, J. E., Anagnostou, V., Cottrell, T. R., Smith, K. N., Verde, F., Zahurak, M., Lanis, M., Murray, J. C., Chan, H. Y., McCarthy, C., Wang, D., White, J. R., Yang, S., Battafarano, R., Broderick, S., Bush, E., Brock, M., Ha, J., Jones, D., Merghoub, T., & 12 othersTaube, J., Velculescu, V. E., Rosner, G., Illei, P., Pardoll, D. M., Topalian, S., Naidoo, J., Levy, B., Hellmann, M. D., Brahmer, J. R., Chaft, J. E. & Forde, P. M., Sep 13 2020, In: Journal for immunotherapy of cancer. 8, 2, e001282.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Ipilimumab 100%
  • Nivolumab 96%
  • Non-Small Cell Lung Carcinoma 63%
  • Neoplasms 16%
  • Mutation 11%
  13 Scopus citations

• Phase i and pharmacokinetic study of romidepsin in patients with cancer and hepatic dysfunction: A national cancer institute organ dysfunction working group study

  ETCTN-9008 Study Team, Oct 15 2020, In: Clinical Cancer Research. 26, 20, p. 5329-5337 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • romidepsin 100%
  • National Cancer Institute (U.S.) 71%
  • Liver Neoplasms 61%
  • Pharmacokinetics 46%
  • Liver 21%

• Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide

  DeZern, A. E., Elmariah, H., Zahurak, M., Rosner, G. L., Gladstone, D. E., Ali, S. A., Huff, C. A., Swinnen, L. J., Imus, P., Borrello, I., Wagner-Johnston, N. D., Ambinder, R. F., Brodsky, R. A., Cooke, K., Luznik, L., Fuchs, E. J., Bolaños-Meade, J. & Jones, R. J., Nov 2020, In: Biology of Blood and Marrow Transplantation. 26, 11, p. 2075-2081 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Duration of Therapy 100%
  • Cyclophosphamide 99%
  • Immunosuppressive Agents 88%
  • Immunosuppression 88%
  • Transplantation 81%
  3 Scopus citations

• The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations

  Ivanova, A., Israel, E., LaVange, L. M., Peters, M. C., Denlinger, L. C., Moore, W. C., Bacharier, L. B., Marquis, M. A., Gotman, N. M., Kosorok, M. R., Tomlinson, C., Mauger, D. T., Georas, S. N., Wright, R. J., Noel, P., Rosner, G. L., Akuthota, P., Billheimer, D., Bleecker, E. R., Cardet, J. C., & 23 othersCastro, M., DiMango, E. A., Erzurum, S. C., Fahy, J. V., Fajt, M. L., Gaston, B. M., Holguin, F., Jain, S., Kenyon, N. J., Krishnan, J. A., Kraft, M., Kumar, R., Liu, M. C., Ly, N. P., Moy, J. N., Phipatanakul, W., Ross, K., Smith, L. J., Szefler, S. J., Teague, W. G., Wechsler, M. E., Wenzel, S. E. & White, S. R., 2020, In: Journal of biopharmaceutical statistics. 30, 6, p. 1026-1037 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Asthma 100%
  • Medical Futility 31%
  • Cross-Over Studies 20%
  • Early Stopping 19%
  • Strategy 19%
  4 Scopus citations
• 2019

  A Bayesian design for phase I cancer therapeutic vaccine trials

  Wang, C., Rosner, G. L. & Roden, R. B. S., Mar 30 2019, In: Statistics in Medicine. 38, 7, p. 1170-1189 20 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Bayesian Design 100%
  • Vaccine 89%
  • Phase I Trial 85%
  • Cancer Vaccines 84%
  • Cancer 71%
  2 Scopus citations

• A Bayesian nonparametric causal inference model for synthesizing randomized clinical trial and real-world evidence

  Wang, C. & Rosner, G. L., Jun 30 2019, In: Statistics in Medicine. 38, 14, p. 2573-2588 16 p.

  Research output: Contribution to journal › Article › peer-review

  • Causal Inference 100%
  • Nonparametric Inference 98%
  • Randomized Clinical Trial 96%
  • Bayesian Nonparametrics 91%
  • Propensity Score 79%
  3 Scopus citations

• Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide

  McCurdy, S. R., Kanakry, C. G., Tsai, H. L., Gojo, I., Smith, B. D., Gladstone, D. E., Bolaños-Meade, J., Borrello, I., Matsui, W. H., Swinnen, L. J., Huff, C. A., Brodsky, R. A., Ambinder, R. F., Fuchs, E. J., Rosner, G. L., Jones, R. J. & Luznik, L., Jun 2019, In: Biology of Blood and Marrow Transplantation. 25, 6, p. 1128-1135 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Graft vs Host Disease 100%
  • Bone Marrow Transplantation 97%
  • Cyclophosphamide 88%
  • Transplants 59%
  • Confidence Intervals 56%
  14 Scopus citations

• Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials

  Paller, C. J., Huang, E. P., Luechtefeld, T., Massett, H. A., Williams, C. C., Zhao, J., Gravell, A. E., Tamashiro, T., Reeves, S. A., Rosner, G. L., Carducci, M. A., Rubinstein, L. & Ivy, S. P., Jun 4 2019, In: Frontiers in Medicine. 6, 122.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Advisory Committees 100%
  • Research Personnel 98%
  • Pharmacokinetics 70%
  • Clinical Trials 61%
  • National Cancer Institute (U.S.) 54%

• Seamless designs: Current practice and considerations for early-phase drug development in oncology

  Hobbs, B. P., Barata, P. C., Kanjanapan, Y., Paller, C. J., Perlmutter, J., Pond, G. R., Prowell, T. M., Rubin, E. H., Seymour, L. K., Wages, N. A., Yap, T. A., Feltquate, D., Garrett-Mayer, E., Grossman, W., Hong, D. S., Ivy, S. P., Siu, L. L., Reeves, S. A. & Rosner, G. L., Feb 1 2019, In: Journal of the National Cancer Institute. 111, 2, p. 118-128 11 p.

  Research output: Contribution to journal › Review article › peer-review

  Open Access

  • Drug Development 100%
  • Investigational Drugs 36%
  • Drug Approval 34%
  • Medical Oncology 31%
  • National Cancer Institute (U.S.) 30%
  17 Scopus citations
• 2018

  A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial

  Santa-Maria, C. A., Bardia, A., Blackford, A. L., Snyder, C., Connolly, R. M., Fetting, J. H., Hayes, D. F., Jeter, S. C., Miller, R. S., Nguyen, A., Quinlan, K., Rosner, G. L., Slater, S., Storniolo, A. M., Wolff, A. C., Zorzi, J., Henry, N. L. & Stearns, V., Aug 1 2018, In: Breast Cancer Research and Treatment. 171, 1, p. 121-129 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Zoledronic Acid 100%
  • Aromatase Inhibitors 94%
  • Letrozole 70%
  • exemestane 51%
  • Pharmacogenetics 38%
  4 Scopus citations

• A phase I trial of a guadecitabine (SGI-110) and irinotecan in metastatic colorectal cancer patients previously exposed to irinotecan

  Lee, V., Wang, J., Zahurak, M., Gootjes, E., Verheul, H. M., Parkinson, R., Kerner, Z., Sharma, A., Rosner, G., De Jesus-Acosta, A., Laheru, D., Le, D. T., Oganesian, A., Lilly, E., Brown, T., Jones, P., Baylin, S., Ahuja, N. & Azad, N., Dec 15 2018, In: Clinical Cancer Research. 24, 24, p. 6160-6167 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • guadecitabine 100%
  • Irinotecan 58%
  • Colorectal Neoplasms 39%
  • Intercellular Signaling Peptides and Proteins 15%
  • Demethylation 14%
  20 Scopus citations

• A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer

  Marrone, K. A., Zhou, X., Forde, P. M., Purtell, M., Brahmer, J. R., Hann, C. L., Kelly, R. J., Coleman, B., Gabrielson, E., Rosner, G. L. & Ettinger, D. S., Jul 2018, In: Oncologist. 23, 7, p. 859-865 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Carboplatin 100%
  • Bevacizumab 99%
  • Metformin 95%
  • Paclitaxel 90%
  • Non-Small Cell Lung Carcinoma 79%
  32 Scopus citations

• Bayesian approaches to evaluating doses of drugs

  Rosner, G., Apr 1 2018, In: Clinical Advances in Hematology and Oncology. 16, 4, p. 258-261 4 p.

  Research output: Contribution to journal › Comment/debate › peer-review

• Dependent generalized Dirichlet process priors for the analysis of acute lymphoblastic leukemia

  Barcella, W., De Iorio, M., Favaro, S. & Rosner, G. L., Jul 1 2018, In: Biostatistics. 19, 3, p. 342-358 17 p.

  Research output: Contribution to journal › Article › peer-review

  • Dirichlet Process Prior 100%
  • Leukemia 76%
  • Acute 67%
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma 58%
  • Lipid Metabolism 57%
  2 Scopus citations

• Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (British journal of cancer (2017) 116 11 (1402-1407))

  Shroff, R. T., Yarchoan, M., O'Connor, A., Gallagher, D., Zahurak, M. L., Rosner, G., Ohaji, C., Sartorius-Mergenthaler, S., Parkinson, R., Subbiah, V., Zinner, R. & Azad, N. S., Jan 1 2018, In: British journal of cancer. 118, 2, p. e2

  Research output: Contribution to journal › Comment/debate › peer-review

  Open Access
  1 Scopus citations

• Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

  Zeidner, J. F., Foster, M. C., Blackford, A. L., Litzow, M. R., Morris, L. E., Strickland, S. A., Lancet, J. E., Bose, P., Levy, M. Y., Tibes, R., Gojo, I., Gocke, C. D., Rosner, G. L., Little, R. F., Wright, J. J., Doyle, L. A., Smith, B. D. & Karp, J. E., Sep 2018, In: Leukemia Research. 72, p. 92-95 4 p.

  Research output: Contribution to journal › Letter › peer-review

  Open Access
  16 Scopus citations

• Grade II Acute Graft-versus-Host Disease and Higher Nucleated Cell Graft Dose Improve Progression-Free Survival after HLA-Haploidentical Transplant with Post-Transplant Cyclophosphamide

  McCurdy, S. R., Kanakry, C. G., Tsai, H. L., Kasamon, Y. L., Showel, M. M., Bolaños-Meade, J., Huff, C. A., Borrello, I., Matsui, W. H., Brodsky, R. A., Ambinder, R. F., Bettinotti, M. P., Fuchs, E. J., Rosner, G. L., Jones, R. J. & Luznik, L., Feb 2018, In: Biology of Blood and Marrow Transplantation. 24, 2, p. 343-352 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Graft vs Host Disease 100%
  • Cyclophosphamide 88%
  • Progression-Free Survival 86%
  • Transplants 59%
  • Confidence Intervals 56%
  33 Scopus citations

• Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non–First-Degree Related Donors

  Elmariah, H., Kasamon, Y. L., Zahurak, M., Macfarlane, K. W., Tucker, N., Rosner, G. L., Bolaños-Meade, J., Fuchs, E. J., Wagner-Johnston, N., Swinnen, L. J., Huff, C. A., Matsui, W. H., Gladstone, D. E., McCurdy, S. R., Borrello, I., Gocke, C. B., Shanbhag, S., Cooke, K. R., Ali, S. A., Brodsky, R. A., & 4 othersDeZern, A. E., Luznik, L., Jones, R. J. & Ambinder, R. F., May 2018, In: Biology of Blood and Marrow Transplantation. 24, 5, p. 1099-1102 4 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haploidentical Transplantation 100%
  • Bone Marrow Transplantation 63%
  • Cyclophosphamide 57%
  • Tissue Donors 48%
  • Transplants 38%
  27 Scopus citations

• Muscadine grape skin extract (MPX) in men with biochemically recurrent prostate cancer: A randomized, multicenter, placebo-controlled clinical trial

  Paller, C. J., Zhou, X. C., Heath, E. I., Taplin, M. E., Mayer, T., Stein, M. N., Bubley, G. J., Pili, R., Hudson, T., Kakarla, R., Abbas, M. M., Anders, N. M., Dowling, D., King, S., Bruns, A. B., Wagner, W. D., Drake, C. G., Antonarakis, E. S., Eisenberger, M. A., Denmeade, S. R., & 3 othersRudek, M. A., Rosner, G. L. & Carducci, M. A., Jan 15 2018, In: Clinical Cancer Research. 24, 2, p. 306-315 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Vitis 100%
  • Controlled Clinical Trials 83%
  • Prostatic Neoplasms 61%
  • Placebos 53%
  • superoxide dismutase 2 45%
  18 Scopus citations

• Neoadjuvant PD-1 blockade in resectable lung cancer

  Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Broderick, S., Yang, S. C., Jones, D. R., Battafarano, R. J., Velez, M. J., Rekhtman, N., Olah, Z., Verde, F., Naidoo, J., Marrone, K. A., Guo, H., Sidhom, J. W., Zhang, J., & 15 othersCaushi, J. X., Chan, H. Y., Scharpf, R. B., White, J., Gabrielson, E., Wang, H., Rosner, G. L., Rusch, V., Wolchok, J. D., Merghoub, T., Taube, J. M., Velculescu, V. E., Topalian, S. L., Brahmer, J. R. & Pardoll, D. M., May 24 2018, In: New England Journal of Medicine. 378, 21, p. 1976-1986 11 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Nivolumab 100%
  • Lung Neoplasms 81%
  • Clone Cells 46%
  • Non-Small Cell Lung Carcinoma 39%
  • T-Lymphocytes 36%
  570 Scopus citations

• Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer

  Litvak, A., Batukbhai, B., Russell, S. D., Tsai, H. L., Rosner, G. L., Jeter, S. C., Armstrong, D., Emens, L. A., Fetting, J., Wolff, A. C., Silhy, R., Stearns, V. & Connolly, R. M., May 1 2018, In: Cancer. 124, 9, p. 1904-1911 8 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Cardiotoxicity 92%
  • Breast Neoplasms 52%
  • European Continental Ancestry Group 41%
  • African Continental Ancestry Group 29%
  • Confidence Intervals 17%
  13 Scopus citations

• Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation

  Kasamon, Y. L., Fuchs, E. J., Zahurak, M., Rosner, G. L., Symons, H. J., Gladstone, D. E., Huff, C. A., Swinnen, L. J., Brodsky, R. A., Matsui, W. H., Borrello, I., Shanbhag, S., Cooke, K. R., Ambinder, R. F., Luznik, L., Bolaños-Meade, J. & Jones, R. J., May 2018, In: Biology of Blood and Marrow Transplantation. 24, 5, p. 1022-1028 7 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haploidentical Transplantation 100%
  • Tacrolimus 66%
  • Graft vs Host Disease 65%
  • Bone Marrow Transplantation 63%
  • Transplantation 41%
  15 Scopus citations
• 2017

  A phase I study of topotecan, carboplatin and the PARP inhibitor veliparib in acute leukemias, aggressive myeloproliferative neoplasms, and chronic myelomonocytic leukemia

  Pratz, K. W., Rudek, M. A., Gojo, I., Litzow, M. R., McDevitt, M. A., Ji, J., Karnitz, L. M., Herman, J. G., Kinders, R. J., Smith, B. D., Gore, S. D., Carraway, H. E., Showel, M. M., Gladstone, D. E., Levis, M. J., Tsai, H. L., Rosner, G., Chen, A., Kaufmann, S. H. & Karp, J. E., Feb 15 2017, In: Clinical Cancer Research. 23, 4, p. 899-907 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • veliparib 100%
  • Leukemia, Myelomonocytic, Chronic 84%
  • Topotecan 79%
  • Poly(ADP-ribose) Polymerase Inhibitors 76%
  • Carboplatin 64%
  20 Scopus citations

• Challenges and opportunities in adapting clinical trial design for immunotherapies

  Siu, L. L., Ivy, S. P., Dixon, E. L., Gravell, A. E., Reeves, S. A. & Rosner, G. L., Sep 1 2017, In: Clinical Cancer Research. 23, 17, p. 4950-4958 9 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Immunotherapy 100%
  • Clinical Trials 73%
  • Thinking 37%
  • Immune System 30%
  • Kinetics 27%
  18 Scopus citations

• Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide

  McCurdy, S. R., Kasamon, Y. L., Kanakry, C. G., Bolaños-Meade, J., Tsai, H. L., Showel, M. M., Kanakry, J. A., Symons, H. J., Gojo, I., Smith, B. D., Bettinotti, M. P., Matsui, W. H., Dezern, A. E., Huff, C. A., Borrello, I., Pratz, K. W., Gladstone, D. E., Swinnen, L. J., Brodsky, R. A., Levis, M. J., & 5 othersAmbinder, R. F., Fuchs, E. J., Rosner, G. L., Jones, R. J. & Luznik, L., 2017, In: Haematologica. 102, 2, p. 391-400 10 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Haploidentical Transplantation 100%
  • Graft vs Host Disease 65%
  • Cyclophosphamide 57%
  • Transplantation 47%
  • Recurrence 31%
  96 Scopus citations

• From famine to feast: Developing early-phase combination immunotherapy trials wisely

  Day, D., Monjazeb, A. M., Sharon, E., Ivy, S. P., Rubin, E. H., Rosner, G. L. & Butler, M. O., Sep 1 2017, In: Clinical Cancer Research. 23, 17, p. 4980-4991 12 p.

  Research output: Contribution to journal › Article › peer-review

  Open Access

  • Famine 100%
  • Immunotherapy 57%
  • Safety 18%
  • Allergy and Immunology 17%
  • Therapeutics 10%
  13 Scopus citations